Novo Nordisk As Stock Book Value Per Share
| NONOF Stock | USD 128.22 1.76 1.39% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Pink Sheet. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk pink sheet.
Novo |
Novo Nordisk AS Company Book Value Per Share Analysis
Novo Nordisk's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Novo Nordisk Book Value Per Share | 37.10 X |
Most of Novo Nordisk's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Novo Nordisk AS is about 37.099 times. This is 2282.29% lower than that of the Healthcare sector and 114.92% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 98.08% higher than that of the company.
Novo Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in book value per share category among related companies.
Novo Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Shares Owned By Institutions | 38.87 % | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X | |||
| Revenue | 176.95 B | |||
| Gross Profit | 148.51 B | |||
| EBITDA | 76.8 B | |||
| Net Income | 55.52 B | |||
| Cash And Equivalents | 31.04 B | |||
| Cash Per Share | 13.68 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 0.34 % | |||
| Current Ratio | 0.94 X | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.53 X | |||
| Price To Earnings To Growth | 1.94 X | |||
| Number Of Employees | 54.39 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 318.05 B | |||
| Total Asset | 241.26 B | |||
| Retained Earnings | 41.06 B | |||
| Working Capital | 9.98 B | |||
| Current Asset | 51.58 B | |||
| Current Liabilities | 41.59 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.78 % | |||
| Net Asset | 241.26 B | |||
| Last Dividend Paid | 12.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Novo Pink Sheet analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |